Tuesday, April 10

Pfizers Continues To Fight For Lipitor Market Share

Following up on their original look at the new, generic alternative to Lipitor (atorvastatin), the good folks at inThought have put out an even more thorough look at how the largest brand in pharmaceutical history is holding up.  Check out the highlights below and, if you're interested, request the entire report for free by email.
  • Pfizer has gone to great lengths to maintain sales of Lipitor in the United States since a generic alternative (atorvastatin) became available on November 30, 2011.
  • The Lipitor For You patient assistance program. which reduces patient out of pocket costs for Lipitor to as little as $4 per prescription, is being used in as many as 1 in 4 eligible transactions [source: ProMetis Dynamic Claims prescription claims data asset].
  • Ranbaxy holds an 180 day exclusivity to manufacturer generic atorvastatin, after which time 10 to 15 more companies are expected to begin producing it.
  • Continued efforts to preserve Lipitor’s market share are expected to result in profitability similar to other blockbuster products which have lost patent exclusivity.

Monday, April 9

Welcome To The Healthcare Analytics Blog

Welcome to the Wolters Kluwer Healthcare Analytics Blog. The idea is to post news, updates, suggestions, and interesting bits of relevant news.

A select handful of experienced insiders from across the healthcare industry will be contributing articles and insights on all sorts of topics - managed care, patient behaviors, third party payors, financial analysis, academic research, and government. We hope you enjoy and join the conversation.